Drugs / arTreg-CSB
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03577431 | Mar 2019 → Feb 2026 overdue | — | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | arTreg-CSB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03577431 ↗ |
| Route | Intravenous | “arTreg-CSB will be administered as a single peripheral intravenous (IV) infusion over approximately 15 to 30 minutes.” NCT03577431 ↗ |